Royce & Associates LP Sells 517,680 Shares of Bio-Techne Corp $TECH

Royce & Associates LP lowered its position in shares of Bio-Techne Corp (NASDAQ:TECH – Free Report) by 65.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 272,065 shares of the biotechnology company’s stock after selling 517,680 shares during the quarter. Royce & Associates LP’s holdings in Bio-Techne were worth $19,717,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of TECH. Tema ETFs LLC boosted its stake in shares of Bio-Techne by 5.4% in the 2nd quarter. Tema ETFs LLC now owns 2,818 shares of the biotechnology company’s stock worth $199,000 after buying an additional 145 shares during the last quarter. ZWJ Investment Counsel Inc. increased its position in shares of Bio-Techne by 4.8% during the third quarter. ZWJ Investment Counsel Inc. now owns 3,971 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 183 shares during the last quarter. Empirical Finance LLC increased its position in shares of Bio-Techne by 4.4% during the second quarter. Empirical Finance LLC now owns 4,478 shares of the biotechnology company’s stock valued at $316,000 after acquiring an additional 189 shares during the last quarter. North Dakota State Investment Board lifted its holdings in Bio-Techne by 4.3% during the third quarter. North Dakota State Investment Board now owns 4,789 shares of the biotechnology company’s stock worth $347,000 after acquiring an additional 196 shares during the period. Finally, Parallel Advisors LLC lifted its holdings in Bio-Techne by 13.2% during the first quarter. Parallel Advisors LLC now owns 1,936 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 225 shares during the period. Institutional investors own 98.95% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on TECH shares. Benchmark reissued a “hold” rating on shares of Bio-Techne in a research report on Wednesday, August 19th. Zacks Research raised Bio-Techne from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 29th. Argus cut Bio-Techne from a “strong-buy” rating to a “strong sell” rating in a research note on Monday, October 26th. Weiss Ratings raised shares of Bio-Techne from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 25th. Finally, Wells Fargo & Company downgraded shares of Bio-Techne from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $62.00 to $73.00 in a report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $68.92.

View Our Latest Analysis on TECH

Bio-Techne Price Performance

Shares of TECH stock opened at $72.80 on Monday. The company has a 50 day moving average of $72.53 and a 200-day moving average of $63.48. Bio-Techne Corp has a 12-month low of $43.19 and a 12-month high of $72.88. The firm has a market cap of $11.44 billion, a P/E ratio of 66.79, a PEG ratio of 5.28 and a beta of 1.29.

Bio-Techne (NASDAQ:TECH – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The biotechnology company reported $0.44 EPS for the quarter, hitting analysts’ consensus estimates of $0.44. Bio-Techne had a net margin of 13.95% and a return on equity of 13.00%. The company had revenue of $299.71 million for the quarter, compared to analysts’ expectations of $292.60 million. As a group, equities analysts expect that Bio-Techne Corp will post 1.75 EPS for the current year.

Bio-Techne Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 23rd. Shareholders of record on Friday, November 13th will be given a $0.08 dividend. This is a decrease from Bio-Techne’s previous quarterly dividend of $0.65. This represents a $0.32 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 13th. Bio-Techne’s dividend payout ratio (DPR) is 29.36%.

About Bio-Techne

(Free Report)

Bio-Techne is a life sciences company that develops and supplies products and services used in biological research, drug development, and clinical diagnostics. Its offerings include proteins, antibodies, immunoassays, and small molecules, as well as instruments and analytical tools for studying cells and biological processes. The company also provides technologies for protein analysis, molecular diagnostics, and spatial biology. Its portfolio includes products and services associated with brands such as R&D Systems, Tocris, ProteinSimple, and Advanced Cell Diagnostics.

Featured Articles

Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Corp (NASDAQ:TECH – Free Report).

Institutional Ownership by Quarter for Bio-Techne (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.